ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1806

Sex differences in knee joint microbial DNA of C57BL/6 mice and the effect of cross-sex microbiome transplantation
Abstract Number: 1808

Lightsheet imaging with 3D analysis for wholistic assessment of synovial lymphatic vasculature within joints of murine models of arthritis
Abstract Number: 1809

Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
Abstract Number: 1810

Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis
Abstract Number: 1811

Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Abstract Number: 1812

Inflammasome and UPR activation in monocytes of HLA B27 positive children with Enthesitis related arthritis category of JIA
Abstract Number: 1813

Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis
Abstract Number: 1814

Trapped in the NET: Impaired DNase function and targeted antibodies in the pathogenesis of pediatric lupus nephritis
Abstract Number: 1815

New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Abstract Number: 1816

Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells
Abstract Number: 1817

Sex-specific mechanisms associated with female childhood-onset systemic lupus erythematosus revealed by transcriptomic analysis of transgender adolescents undergoing gender-affirming sex hormone therapy.
Abstract Number: 1818

Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
Abstract Number: 1819

Spatial Transcriptomic Profiling Reveals Interferon Activation and CD8⁺ T Cell Dominance in Systemic Juvenile Idiopathic Arthritis-Macrophage Activation Syndrome Liver Inflammation
Abstract Number: 1820

Cytokine profiling in refractory systemic juvenile idiopathic arthritis reveals distinct signatures for macrophage activation syndrome and lung disease.
Abstract Number: 1821

Transcriptiomics of tear RNA from children with active and inactive chronic anterior uveitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].